Hugel officially entered the Indian market with Letybo, setting a 9% market-share target by 2026. India's botulinum toxin market is fragmented and growing rapidly, with local and multinational players competing on price and distribution. Hugel's entry adds pressure to established players like Allergan and Galderma in a region where per-unit pricing is substantially lower than North America and Europe.